Cancer Letters
Volume 286, Issue 1 , Pages 44-51 , 1 December 2009

Molecular pathogenesis and early detection of hepatocellular carcinoma – Perspectives from West Africa

  • Maimuna Mendy

      Affiliations

    • Medical Research Council Laboratories, Fajara, Gambia, West Africa
    • ,
  • Robert Walton

      Affiliations

    • Centre for Health Sciences, Barts and the London Medical School, Abernethy Building, London E1 2AT, United Kingdom
    • Corresponding Author InformationCorresponding author.

Received 17 November 2008 ,Revised 26 March 2009 ,Accepted 23 April 2009.

References 

  1. Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, et al. 20 years into the Gambia hepatitis intervention study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol. Biomarkers Prev. 2008;17:3216–3223
  2. Turner PC, Sylla A, Gong YY, Diallo MS, Sutcliffe AE, Hall AJ, et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in West Africa: a community-based intervention study. Lancet. 2005;365:1950–1956
  3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005;55:74–108
  4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  5. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942–1956
  6. Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut. 1993;34:S13–S16
  7. Kirk GD, Turner PC, Gong Y, Lesi OA, Mendy M, Goedert JJ, et al. Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol. Biomarkers Prev. 2005;14:373–379
  8. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer. 1998;75:347–354
  9. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br. J. Cancer. 2005;92:607–612
  10. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis. 2001;22:535–545
  11. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature. 1991;350:429–431
  12. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 2004;36:55–62
  13. Kirk GD, Lesi OA, Mendy M, Szymanska K, Whittle H, Goedert JJ, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005;24:5858–5867
  14. Montesano R, Hainaut P, Wild CP. Hepatocellular carcinoma: from gene to public health. J. Natl. Cancer Inst. 1997;89:1844–1851
  15. Sylla A, Diallo MS, Castegnaro J, Wild CP. Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach. Mutat. Res. 1999;428:187–196
  16. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121–124
  17. Di Maio M, Daniele B, Pignata S, Gallo C, De Maio E, Morabito A, et al. Is human hepatocellular carcinoma a hormone-responsive tumor?. World J. Gastroenterol. 2008;14:1682–1689
  18. Jie X, Lang C, Jian Q, Chaoqun L, Dehua Y, Yi S, et al. Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene. 2007;26:5741–5751
  19. Chiu CM, Yeh SH, Chen PJ, Kuo TJ, Chang CJ, Yang WJ, et al. Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proc. Natl. Acad. Sci. USA. 2007;104:2571–2578
  20. D’Amico F, Biancolella M, Margiotti K, Reichardt JK, Novelli G. Genomic biomarkers, androgen pathway and prostate cancer. Pharmacogenomics. 2007;8:645–661
  21. Westin J, Lagging LM, Wejstal R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver. 1999;19:183–187
  22. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–1457
  23. Alpert ME, Uriel J, de Nechaud B. Alpha-1 fetoglobulin in the diagnosis of human hepatoma. N. Engl. J. Med. 1968;278:984–986
  24. Takashima T, Matsui O, Suzuki M, Ida M. Diagnosis and screening of small hepatocellular carcinomas. Comparison of radionuclide imaging, ultrasound, computed tomography, hepatic angiography, and alpha 1-fetoprotein assay. Radiology. 1982;145:635–638
  25. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 1990;12:1420–1432
  26. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747–1753
  27. Spangenberg HC, Lee HB, Li J, Tan F, Skidgel R, Wands JR, et al. A short sequence within domain C of duck carboxypeptidase D is critical for duck hepatitis B virus binding and determines host specificity. J. Virol. 2001;75:10630–10642(JID – 0113724)
  28. Mendy M, Kirk GD, van der Sande M, Jeng-Barry A, Lesi OA, Hainaut P, et al. Hepatitis B surface antigenaemia and alpha-foetoprotein detection from dried blood spots: applications to field-based studies and to clinical care in hepatitis B virus endemic areas. J. Viral Hepat. 2005;12:642–647
  29. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225–1241
  30. Marrero JA. Hepatocellular carcinoma. Curr. Opin. Gastroenterol. 2006;22:248–253
  31. Marrero JA. Screening tests for hepatocellular carcinoma. Clin. Liver Dis. 2005;9:235–251vi
  32. Paterson AC, Kew MC, Herman AA, Becker PJ, Hodkinson J, Isaacson C. Liver morphology in Southern African blacks with hepatocellular carcinoma: a study within the urban environment. Hepatology. 1985;5:72–78
  33. Kew MC. Clinical, pathologic, and etiologic heterogeneity in hepatocellular carcinoma: evidence from Southern Africa. Hepatology. 1981;1:366–369
  34. Mendy ME, McConkey SJ, Sande van der MA, Crozier S, Kaye S, Jeffries D, et al. Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia. Virol. J. 2008;5:49
  35. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995;22:1387–1392
  36. Attia KA, Ackoundou-N’guessan C, N’Dri-Yoman KAT, Mahassadi AK, Messou E, Bathaix YF, et al. Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients. World J. Gastroenterol. 2008;14:286–291
  37. Lesi OA, Kehinde MO, Anomneze EE. Chronic liver disease in Lagos: a clinicopathological study. Niger. Postgrad. Med. J. 2004;11:91–96
  38. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp. Hepatol. 2004;3:8
  39. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin. Chem. 2006;52:1887–1896
  40. Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL, Sampaio JP, Lanzoni VP, Ferraz ML, et al. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver Int. 2008;28:486–493
  41. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526
  42. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22:5093–5107
  43. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology. 1995;38:24–34(Review, 57 refs)
  44. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J. Gen. Virol. 2000;81 Pt 1:67–74
  45. Kramvis A, Kew M, Francois G. Hepatitis B virus genotypes. Vaccine. 2005;23:2409–2423
  46. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus – large-scale analysis using a new genotyping method. J. Infect. Dis. 1997;175:1285–1293(JID – 0413675)
  47. Dumpis U, Holmes EC, Mendy M, Hill A, Thursz M, Hall A, et al. Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. J. Hepatol. 2001;35:99–104
  48. Dai CY, Yu ML, Chuang WL, Lu SN, Wang JH, Huang JF, et al. The epidemiology of TT virus (TTV) infection in a hepatitis C and B virus hyperendemic area of Southern Taiwan. Kaohsiung J. Med. Sci. 2000;16:500–509
  49. Amini-Bavil-Olyaee S, Sarrami-Forooshani R, Mahboudi F, Sabahi F, Adeli A, Noorinayer B, et al. Genotype characterization and phylogenetic analysis of hepatitis B virus isolates from Iranian patients. J. Med. Virol. 2005;75:227–234
  50. Kramvis A, Kew MC, Bukofzer S. Hepatitis B virus precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma. J. Hepatol. 1998;28:132–1341
  51. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J. Infect. Dis. 2006;194:594–599
  52. Fang ZL, Sabin CA, Dong BQ, Ge LY, Wei SC, Chen QY, et al. G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am. J. Gastroenterol. 2008;103:2254–2262
  53. Mendy ME, Kaye S, Le Roux E, Kirk GD, Jeng-Barry A, McConkey S, et al. Rowland-Jones, and H. Whittle, Application of a novel, rapid, and sensitive oligonucleotide ligation assay for detection of cancer-predicting mutations in the precore and basal core promoter of hepatitis B virus. J. Clin. Microbiol. 2008;46:2723–2730
  54. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J. Biomed. Sci. 2008;15:137–145
  55. Baumert TF, Thimme R, von Weizsacker F. Pathogenesis of hepatitis B virus infection. World J. Gastroenterol. 2007;13:82–90
  56. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in Sub-Saharan Africa. Lancet Infect. Dis. 2002;2:293–302
  57. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, et al. The Gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004;39:211–219
  58. Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M, et al. Environmental and genetic determinants of aflatoxin–albumin adducts in The Gambia. Int. J. Cancer. 2000;86:1–7
  59. Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. N. Engl. J. Med. 2004;350:1118–1129
  60. Wright TL. Introduction to chronic hepatitis B infection. Am. J. Gastroenterol. 2006;101(Suppl. 1):S1–S6
  61. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. Ann. Surg. Oncol. 2008;15:962–971
  62. Beneduce L, Castaldi F, Marino M, Tono N, Gatta A, Pontisso P, et al. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP–IgM complexes. Int. J. Biol. Markers. 2004;19:155–159
  63. Khien VV, Mao HV, Chinh TT, Ha PT, Bang MH, Lac BV, et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int. J. Biol. Markers. 2001;16:105–111
  64. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnu L, et al. Squamous cell carcinoma antigen–immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer. 2005;103:2558–2565
  65. Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P, et al. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int. J. Cancer. 2005;117:506–509
  66. Saitoh S, Ikeda K, Koida I, Tsubota A, Arase Y, Chayama K, et al. Small hepatocellular carcinoma: evaluation of portal blood flow with CT during arterial portography performed with balloon occlusion of the hepatic artery. Radiology. 1994;193:67–70
  67. Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006;44:1012–1024
  68. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001;48:558–564
  69. Man XB, Tang L, Zhang BH, Li SJ, Qiu XH, Wu MC, et al. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int. 2005;25:962–966
  70. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 2004;64:2418–2423
  71. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 2000;342:1350–1358
  72. Wouters BG. Proteomics: methodologies and applications in oncology. Semin. Radiat. Oncol. 2008;18:115–125
  73. Clarke W, Zhang Z, Chan DW. The application of clinical proteomics to cancer and other diseases. Clin. Chem. Lab. Med. 2003;41:1562–1570
  74. Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin. Chem. 2005;51:328–335
  75. Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin. Chem. 2003;49:752–760
  76. Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol. Today. 1990;11:237–244
  77. Carrington M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr. Top Microbiol. Immunol. 2006;298:225–257
  78. Chen Y, Cheng M, Tian Z. Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell. Mol. Immunol. 2006;3:373–378
  79. Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer. 1998;83:58–63
  80. Chuang WL, Liu HW, Chang WY. Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer. 1990;65:926–930
  81. Butsch Kovacic M, Martin M, Gao X, Fuksenko T, Chen CJ, Cheng YJ, et al. Variation of the killer cell immunoglobulin-like receptors and HLA-C genes in nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 2005;14:2673–2677
  82. Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med. 2005;201:1069–1075
  83. Lopez-Vazquez A, Rodrigo L, Martinez-Borra J, Perez R, Rodriguez M, Fdez-Morera JL, et al. Protective effect of the HLA–Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Infect. Dis. 2005;192:162–165
  84. Lopez-Vazquez A, Rodrigo L, Lopez-Larrea C. Association of killer immunoglobulin-like receptors and their HLA Class I ligands with progression of chronic hepatitis C virus infection. Tissue Antigens. 2007;69(Suppl. 1):241–242
  85. Martin MP, Carrington M. Immunogenetics of viral infections. Curr. Opin. Immunol. 2005;17:510–516
  86. Qi Y, Martin MP, Gao X, Jacobson L, Goedert JJ, Buchbinder S, et al. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2006;2:e79
  87. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H, et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 2004;34:1673–1679
  88. Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, Yawata M, et al. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 2007;178:33–37
  89. Gillespie GM, Bashirova A, Dong T, McVicar DW, Rowland-Jones SL, Carrington M. Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8+ T cell epitopes. AIDS Res. Hum. Retroviruses. 2007;23:451–455
  90. Zhi-ming L, Yu-lian J, Zhao-lei F, Chun-xiao W, Zhen-fang D, Bing-chang Z, et al. Polymorphisms of killer cell immunoglobulin-like receptor gene: possible association with susceptibility to or clearance of hepatitis B virus infection in Chinese Han population. Croat. Med. J. 2007;48:800–806
  91. Cui R, He J, Zhang F, Wang B, Ding H, Shen H, et al. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br. J. Cancer. 2003;88:1878–1882
  92. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology. 2004;127:S113–S119
  93. Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, et al. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Br. J. Cancer. 1997;75:1460–1466
  94. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 2002;31:339–346
  95. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene. 2006;25(27):3778–3786

PII: S0304-3835(09)00321-8

doi: 10.1016/j.canlet.2009.04.039

Cancer Letters
Volume 286, Issue 1 , Pages 44-51 , 1 December 2009

Article Tools

* Image Usage & Resolution